Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-02

Clinical Trial Update: CAP-Ketamine for Antidepressant Resistant PTSD [Phase 2]

View source ↗

Summary

Phase 2 trial update for CAP-Ketamine in antidepressant-resistant PTSD; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CAP-Ketamine

Snippet

Sponsor: VA Office of Research and Development | Conditions: PTSD, Posttraumatic Stress Disorder | Phase 2 | Status: COMPLETED | Results posted: 2022-06-02